Literature DB >> 19699505

In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli.

Marietta Weiss1, Emmanuel Denou, Anne Bruttin, Ruth Serra-Moreno, Marie-Lise Dillmann, Harald Brüssow.   

Abstract

The gut transit of T4 phages was studied in axenic mice mono-colonized with the non-pathogenic Escherichia coli strain K-12. Thirty minutes, 1 and 2 h after phage feeding, T4 phage had reached the jejunum, ileum and cecum, respectively. Phage was found in the lumen and was also associated with the mucosa. One day later no phage was detected in the feces. Compared to germ-free control animals, oral T4 phage led to a 300-fold higher fecal phage titer in mice mono-colonized with E. coli strain WG-5. The in vivo T4 phage replication was transient and reached peak fecal titers about 8 h after oral phage application followed by a rapid titer decrease over two days. Similar data were obtained in mice colonized with E. coli strain Nissle. In contrast, orally applied T7 phage experienced a massive and sustained in vivo replication in mice mono-colonized with E. coli strain WG-5 irrespective whether phage or E. coli host was applied first. T7 phage replication occurred mainly in the large intestine. High titers of T7 phage and high E. coli cell counts coexisted in the feces. The observation of only 20% T7 phage-resistant fecal E. coli colonies suggests a refuge model where phage-sensitive E. coli cells are physically or physiologically protected from phage infection in the gut. The difference between T7 and T4 with respect to gut replication might partly reflect their distinct in vitro capacity to replicate on slowly growing cells.

Entities:  

Mesh:

Year:  2009        PMID: 19699505     DOI: 10.1016/j.virol.2009.07.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  41 in total

1.  Safety of using Escherichia coli bacteriophages as a sanitizing agent based on inflammatory responses in rats.

Authors:  Ji-Yeon Hwang; Jung-Eun Kim; Yoon-Jae Song; Jong-Hyun Park
Journal:  Food Sci Biotechnol       Date:  2016-02-29       Impact factor: 2.391

Review 2.  Microbiome therapeutics - Advances and challenges.

Authors:  Mark Mimee; Robert J Citorik; Timothy K Lu
Journal:  Adv Drug Deliv Rev       Date:  2016-05-05       Impact factor: 15.470

Review 3.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Authors:  Krystyna Dąbrowska; Stephen T Abedon
Journal:  Microbiol Mol Biol Rev       Date:  2019-10-30       Impact factor: 11.056

4.  Gnotobiotic mouse model of phage-bacterial host dynamics in the human gut.

Authors:  Alejandro Reyes; Meng Wu; Nathan P McNulty; Forest L Rohwer; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-20       Impact factor: 11.205

5.  Phage treatment of human infections.

Authors:  Stephen T Abedon; Sarah J Kuhl; Bob G Blasdel; Elizabeth Martin Kutter
Journal:  Bacteriophage       Date:  2011-03

6.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

7.  A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli.

Authors:  J J Bull; E R Vimr; I J Molineux
Journal:  Virology       Date:  2009-12-16       Impact factor: 3.616

8.  Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine.

Authors:  Damien Maura; Matthieu Galtier; Chantal Le Bouguénec; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

Review 9.  Going viral: next-generation sequencing applied to phage populations in the human gut.

Authors:  Alejandro Reyes; Nicholas P Semenkovich; Katrine Whiteson; Forest Rohwer; Jeffrey I Gordon
Journal:  Nat Rev Microbiol       Date:  2012-08-06       Impact factor: 60.633

10.  The enemy from within: a prophage of Roseburia intestinalis systematically turns lytic in the mouse gut, driving bacterial adaptation by CRISPR spacer acquisition.

Authors:  Jeffrey K Cornuault; Elisabeth Moncaut; Valentin Loux; Aurélie Mathieu; Harry Sokol; Marie-Agnès Petit; Marianne De Paepe
Journal:  ISME J       Date:  2019-12-11       Impact factor: 10.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.